Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial

Frances Humby(William Harvey Research Institute), Raquel Celis, Bernard Lauwerys(UCLouvain), Juan D. Cañete(Hospital Clínic de Barcelona), Joanna Peel, Gaye Hadfield, Liliane Fossati‐Jimack, Julio Ramírez, Christopher Holroyd(Southampton General Hospital), Arthur G. Pratt, Vasco C. Romão(University of Lisbon), Carlomaurizio Montecucco(University of Pavia), Rebecca Hands, Giovanni Giorli(Queen Mary University of London), Louise Warren, Peter Sasieni(Queen Mary University of London), Mattia Bellan(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Pier Paolo Sainaghi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Hasan Rizvi(Queen Mary University of London), Alberto Cauli(University of Cagliari), Felice Rivellese(Queen Mary University of London), Maya H Buch(University of Manchester), João Eurico Fonseca, John D. Isaacs(Newcastle upon Tyne Hospitals NHS Foundation Trust), Myles Lewis(Brigham and Women's Hospital), Nagui Gendi(Basildon Hospital), Costantino Pitzalis(Guy's Hospital), Pauline Ho(Manchester Royal Infirmary), Bhaskar Dasgupta(Southend University Hospital NHS Foundation Trust), Serena Bugatti, Mattia Congia, Robert J. Moots(University of Liverpool), Ernest Choy(King's College London), Christopher J Edwards(University Hospital Southampton NHS Foundation Trust), Patrick Durez(Cliniques Universitaires Saint-Luc), Patrick Verschueren(KU Leuven), Peter C. Taylor(Nuffield Orthopaedic Centre), Stephen Kelly(Barts Health NHS Trust), Georgina Thorborn, Laura White, Piero Reynolds(Homerton University Hospital), Arti Mahto(King's College Hospital NHS Foundation Trust), Nora Ng(Guy's and St Thomas' NHS Foundation Trust), Charlotte Thompson, Alessandra Nerviani(Queen Mary University of London)
The Lancet
January 1, 2021
Cited by 315


Related Papers